Skip to main content

Advertisement

SpringerLink
Log in

New approaches for cancer immunotherapy

  • Review
  • Published:
Tumor Biology

Abstract

Immunotherapy is a promising field that offers alternative methods for treatment of cancer. The current strategy consists of cancer vaccines, monoclonal antibodies, and cellular therapies. Cancer vaccines aim to eradicate cancer cells via immune system. Thus, they may attack these cells derived from any type of cancer, besides their role in preventing cancer. Lymphocytes and dendritic cells are often used in cellular therapy. In addition, monoclonal antibodies are designed to target specific antigens found in cancer cells. Currently, at least 12 clinically approved monoclonal antibodies are being used and many cancer vaccines are being developed with ongoing phase studies for cancer therapy. Relevant studies are focused on glioma and several other cancer types. Correspondingly, the combination of effective methods may enhance the efficacy of immunotherapy. It is thought that particularly immune checkpoint inhibitors will play a crucial role in immunotherapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–80.

  2. Çağrı Ş, Halit C, Kenan İ. Kanser İmmün Terapi ve MonoklonalAntikorlar. Fırat Üniv Sağlık Bilimleri Tıp Derg. 2013;27(2):105–10.

    Google Scholar 

  3. Old LJ, Scott AM, Wolchok JD. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.

    Article  PubMed  Google Scholar 

  4. Andrea S, Hans S, Mary P. Specificity in cancer immunotherapy. Semin Immunol. 2008;20(5):276–85.

    Article  Google Scholar 

  5. Rini B. Future approaches in immunotherapy. Semin Immunol. 2014;5:30–40.

    Google Scholar 

  6. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117(6):1466–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1:12.

  8. Akiko K, Akira I, Chie O, Ken Y, Koichi M, Masaru K, et al. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. Immunol Lett. 2014;159:15–22.

    Article  Google Scholar 

  9. Hiroaki W, Jianfang N, Samuel D. Immunovirotherapy for glioblastoma. Cell Cycle. 2014;13(2):175–6.

    Article  Google Scholar 

  10. Ming X, Ping Z, Wei H, Yu Y, Zhebao W. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells. J Neuro-Oncol. 2014;116:497–504.

    Article  Google Scholar 

  11. Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther. 2014;21:38–44.

  12. Anna D, Edward V, Emma S, Sofia E. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. Int J Cancer. 2014;134:2748–53.

    Article  Google Scholar 

  13. Bart T, Brown CE, Emanuela B, Katherine W, Prakash S, Sadhak S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology. 2014;16(10):1304–12.

    Article  Google Scholar 

  14. Alexander S, Fabian W, Isabel T, Michael W. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology. 2014;16(3):382–91.

    Article  Google Scholar 

  15. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.

  16. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword. Oncotarget. 2014;5(16):6558–72.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biochemistry, Medical School, Ege University, Izmir, Turkey

    Ayfer Karlitepe

  2. Department of Medical Biology, Medical School, Ege University, Izmir, Turkey

    Ozgun Ozalp & Cigir Biray Avci

Authors
  1. Ayfer Karlitepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozgun Ozalp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cigir Biray Avci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cigir Biray Avci.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karlitepe, A., Ozalp, O. & Avci, C.B. New approaches for cancer immunotherapy. Tumor Biol. 36, 4075–4078 (2015). https://doi.org/10.1007/s13277-015-3491-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3491-2

Keywords

Search

Navigation